诺和诺德导演了一场双输的剧情。就在6月23日,丹麦制药巨头诺和诺德忽然宣布解除与知名远程医疗平台hims&hers Health(简称HIMS)的合作,不再为其提供FDA批准的减肥药Wegovy(其活性成分就是大名鼎鼎的司美格鲁肽)。在这项声明中,诺和诺德直指HIMS平台存在大规模配药,伪装成个性化疗法,以及危及患者健康的欺骗性营销等问题。诺和诺德美国业务执行副总裁Dave Moore言辞激烈地...
Source Link诺和诺德导演了一场双输的剧情。就在6月23日,丹麦制药巨头诺和诺德忽然宣布解除与知名远程医疗平台hims&hers Health(简称HIMS)的合作,不再为其提供FDA批准的减肥药Wegovy(其活性成分就是大名鼎鼎的司美格鲁肽)。在这项声明中,诺和诺德直指HIMS平台存在大规模配药,伪装成个性化疗法,以及危及患者健康的欺骗性营销等问题。诺和诺德美国业务执行副总裁Dave Moore言辞激烈地...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.